Persistence of probiotic strains in the gastrointestinal tract when administered as capsules, yoghurt, or cheese

被引:120
作者
Saxelin, Maija [1 ]
Lassig, Anna
Karjalainen, Heli [1 ]
Tynkkynen, Soile [1 ]
Surakka, Anu [1 ]
Vapaatalo, Heikki [2 ]
Jarvenpaa, Salme [3 ]
Korpela, Riitta [1 ,2 ]
Mutanen, Marja
Hatakka, Katja [1 ]
机构
[1] Valio Ltd, Res & Dev, FI-00039 Helsinki, Finland
[2] Univ Helsinki, Inst Biomed, FI-00014 Helsinki, Finland
[3] MedCare Fdn, FI-44100 Aanekoski, Finland
关键词
Probiotic bacteria; Food matrix; Persistence in gastrointestinal tract; Lactobacillus; Bifidobacterium; Propionibacterium; LACTOBACILLUS-RHAMNOSUS GG; REAL-TIME PCR; IRRITABLE-BOWEL-SYNDROME; LONG-TERM CONSUMPTION; HEALTHY-YOUNG ADULTS; DOSE-RESPONSE; BIFIDOBACTERIUM-LACTIS; COLONIC-MUCOSA; FECAL SAMPLES; MUCUS BINDING;
D O I
10.1016/j.ijfoodmicro.2010.10.009
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
Most clinical studies of probiotics use freeze-dried, powdered bacteria or bacteria packed in capsules. However, probiotics are commercially available in various food matrices, which may affect their persistence in the gastrointestinal tract. The objective of the study was to compare oral and faecal recovery during and after administration of a combination of Lactobacillus rhamnosus GG and LC705, Propionibacterium freudenreichii subsp. shermanii JS. and Bifidobacterium animalis subsp. lactis Bb12 as capsules, yoghurt, or cheese. This randomized, parallel-group, open-label trial (n = 36) included a 4-week run-in, 2-week intervention, and 3-week follow-up period. Participants consumed 10(10) cfu/day of probiotic combination and provided saliva and faecal samples before, during, and after the intervention. Strain-specific real-time PCR was used to quantify the strains. L. rhamnosus GG was the only probiotic strain regularly recovered in saliva samples. During the intervention period it was recovered in the saliva of 88% of the volunteers at least once. No difference was found between the yoghurt and cheese groups. At the end of the intervention, L rhamnosus GG and LC705 counts were high in faecal samples of all product groups (8.08 and 8.67 log(10) genome copies/g, respectively). There was no matrix effect on strain quantity in faeces or the recovery time after ceasing the intervention. For P. freudenreichii subsp. shermanii JS and B. animalis subsp. lactis Bb12, a matrix effect was found at the end of the intervention (P<0.01 and P<0.001, respectively) and in the recovery time during follow-up (P<0.05 for both). Yoghurt yielded the highest faecal quantity of JS and Bb12 strains (8.01 and 9.89 log(10) genome copies/g, respectively). The results showed that the administration matrix did not influence the faecal quantity of lactobacilli, but affected faecal counts of propionibacteria and bifidobacteria that were lower when consumed in cheese. Thus, the consumption of probiotics in yoghurt matrix is highly suitable for studying potential health benefits and capsules provide a comparable means of administration when the viability of the strain in the capsule product is confirmed. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:293 / 300
页数:8
相关论文
共 50 条
[31]   An experimental study and a randomized, double-blind, placebo-controlled clinical trial to evaluate the antisecretory activity of Lactobacillus acidophilus strain LB against nonrotavirus diarrhea [J].
Moal, Vanessa Lievin-Le ;
Sarrazin-Davila, Luis E. ;
Servin, Alain L. .
PEDIATRICS, 2007, 120 (04) :e795-e803
[32]   The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: Mucins, antimicrobial peptides, and microbiota [J].
Moal, VLL ;
Servin, AL .
CLINICAL MICROBIOLOGY REVIEWS, 2006, 19 (02) :315-+
[33]   Probiotic intervention decreases serum gastrin-17 in Helicobacter pylori infection [J].
Myllyluoma, E. ;
Kajander, K. ;
Mikkola, H. ;
Kyronpalo, S. ;
Rasmussen, M. ;
Kankuri, E. ;
Sipponen, P. ;
Vapaatalo, H. ;
Korpela, R. .
DIGESTIVE AND LIVER DISEASE, 2007, 39 (06) :516-523
[34]   Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy -: a placebo-controlled, double-blind randomized pilot study [J].
Myllyluoma, E ;
Veijola, L ;
Ahlroos, T ;
Tynkkynen, S ;
Kankuri, E ;
Vapaatalo, H ;
Rautelin, H ;
Korpela, R .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (10) :1263-1272
[35]   Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children [J].
Näse, L ;
Hatakka, K ;
Savilahti, E ;
Saxelin, M ;
Pönkä, A ;
Poussa, T ;
Korpela, R ;
Meurman, JH .
CARIES RESEARCH, 2001, 35 (06) :412-420
[36]  
Ouwehand AC, 2000, LETT APPL MICROBIOL, V30, P10, DOI 10.1046/j.1472-765X.2000.00590.x
[37]   GROWTH PROMOTION OF BIFIDOBACTERIUM SPECIES BY WHEY AND CASEIN FRACTIONS FROM HUMAN AND BOVINE-MILK [J].
PETSCHOW, BW ;
TALBOTT, RD .
JOURNAL OF CLINICAL MICROBIOLOGY, 1990, 28 (02) :287-292
[38]   Identification, detection, and enumeration of human Bifidobacterium species by PCR targeting the transaldolase gene [J].
Requena, T ;
Burton, J ;
Matsuki, T ;
Munro, K ;
Simon, MA ;
Tanaka, R ;
Watanabe, K ;
Tannock, GW .
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2002, 68 (05) :2420-2427
[39]   Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR [J].
Rinttilä, T ;
Kassinen, A ;
Malinen, E ;
Krogius, L ;
Palva, A .
JOURNAL OF APPLIED MICROBIOLOGY, 2004, 97 (06) :1166-1177
[40]   Survival of Bifidobacterium animalis DN-173 010 in the faecal microbiota after administration in lyophilised form or in fermented product -: A randomised study in healthy adults [J].
Rochet, Violaine ;
Rigottier-Gois, Lionel ;
Ledaire, Audrey ;
Andrieux, Claude ;
Sutren, Malene ;
Rabot, Sylvie ;
Mogenet, Agnes ;
Bresson, Jean-Louis ;
Cools, Stephanie ;
Picard, Celine ;
Goupil-Feuillerat, Nathalie ;
Dore, Joel .
JOURNAL OF MOLECULAR MICROBIOLOGY AND BIOTECHNOLOGY, 2008, 14 (1-3) :128-136